The combination of dehydroepiandrosterone, transdermal testosterone, and growth hormone as an adjuvant therapy in assisted reproductive technology cycles in patients aged below 40 years with diminished ovarian reserve
Göster/ Aç
Tarih
2015Yazar
Haydardedeoglu, Bulent
Isik, Ahmet Zeki
Kilicdag, Esra Bulgan
Üst veri
Tüm öğe kaydını gösterÖzet
Objective: To evaluate to the efficacy of testosterone, dehydroepiandrosterone (DHEA) and growth hormone (GH) supplementations in patients with diminished ovarian reserve (DOR) in assisted reproductive technology (ART) cycles.
Materials and Methods: A retrospective cohort including 33 women with 81 ART cycles were aged and ovarian reserve matched 52 women with 102 conventional in vitro fertilization (IVF)/intra-cytoplasmic sperm injection (ICSI) protocol. Administration of DHEA for 12 weeks and transdermal testosterone for 4 weeks as pretreatment adjuvant and luteal start GH in DOR patient treatment arm compared to conventional IVF/ICSI cycles.
Results: The number of follicles > 14 mm, number of oocytes, number of metaphase 2 oocytes and fertilisation rate were significantly higher in ISIK protocol (IP). The clinical pregnancy rate (CPR) per embryo transfer of the IP was 38.2% (13/34). The cancellation rate of cycles decreased significantly from 54.5 % (24/44) to 8.1% (3/37) with the IP, while the OPR was 35.3% (12/34).
Conclusions: Our study has shown that even the poorest responders could achieve clinical pregnancy after inducing ovarian folliculogenesis with a combination of transdermal testosterone, DHEA.
Koleksiyonlar
- PubMed Açık Erişimli Yayınlar [1472]
- PubMed İndeksli Yayınlar Koleksiyonu [2382]
- Scopus İndeksli Yayınlar Koleksiyonu [3057]
- Tıp Fakültesi / Faculty of Medicine [5916]
- TR-Dizin Açık Erişimli Yayınlar [896]
- TR-Dizin İndeksli Yayınlar Koleksiyonu [984]
- Wos Açık Erişimli Yayınlar [2402]
- Wos İndeksli Yayınlar Koleksiyonu [4123]